Khuri FR - Search Results

1

Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK. Khuri FR, et al. J Natl Cancer Inst. 2006 Apr 5;98(7):441-50. doi: 10.1093/jnci/djj091. J Natl Cancer Inst. 2006. PMID: 16595780 Clinical Trial.

2

Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.

Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E Jr, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK. Shin DM, et al. Among authors: khuri fr. Cancer. 2002 Jul 15;95(2):322-30. doi: 10.1002/cncr.10661. Cancer. 2002. PMID: 12124833 Free article. Clinical Trial.

3

Emerging drugs for head and neck cancer.

Rhee JC, Khuri FR, Shin DM. Rhee JC, et al. Among authors: khuri fr. Expert Opin Emerg Drugs. 2004 May;9(1):91-104. doi: 10.1517/eoed.9.1.91.32953. Expert Opin Emerg Drugs. 2004. PMID: 15155138 Review.

4

Prevention of head and neck cancer: current status and future prospects.

Jain S, Khuri FR, Shin DM. Jain S, et al. Among authors: khuri fr. Curr Probl Cancer. 2004 Sep-Oct;28(5):265-86. doi: 10.1016/j.currproblcancer.2004.05.003. Curr Probl Cancer. 2004. PMID: 15375804 Review. No abstract available.

5

Moving toward bioadjuvant approaches to head and neck cancer prevention.

Saba NF, Hammond A, Shin DM, Khuri FR. Saba NF, et al. Among authors: khuri fr. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S132-5. doi: 10.1016/j.ijrobp.2007.05.041. Int J Radiat Oncol Biol Phys. 2007. PMID: 17848282 Review.

6

Targeting angiogenesis in head and neck cancer.

Saba NF, Shin DM, Khuri FR. Saba NF, et al. Among authors: khuri fr. Curr Cancer Drug Targets. 2007 Nov;7(7):643-9. doi: 10.2174/156800907782418356. Curr Cancer Drug Targets. 2007. PMID: 18045069 Review.

7

Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.

Shin DM, Khuri FR. Shin DM, et al. Among authors: khuri fr. Head Neck. 2013 Mar;35(3):443-53. doi: 10.1002/hed.21910. Epub 2011 Nov 2. Head Neck. 2013. PMID: 22052826 Review.

8

Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract.

Spitz MR, Lippman SM, Jiang H, Lee JJ, Khuri F, Hsu TC, Trizna Z, Schantz SP, Benner S, Hong WK. Spitz MR, et al. J Natl Cancer Inst. 1998 Feb 4;90(3):243-5. doi: 10.1093/jnci/90.3.243. J Natl Cancer Inst. 1998. PMID: 9462683 No abstract available.

9

Molecular epidemiology and retinoid chemoprevention of head and neck cancer.

Khuri FR, Lippman SM, Spitz MR, Lotan R, Hong WK. Khuri FR, et al. J Natl Cancer Inst. 1997 Feb 5;89(3):199-211. doi: 10.1093/jnci/89.3.199. J Natl Cancer Inst. 1997. PMID: 9017000 Review.

10

Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang KK, Lippman SM, Hong WK. Shin DM, et al. Among authors: khuri fr. Cancer. 2001 Apr 1;91(7):1316-23. doi: 10.1002/1097-0142(20010401)91:7<1316::aid-cncr1134>3.0.co;2-0. Cancer. 2001. PMID: 11283932 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

479 results

Search Page